New vaccine included in WHO
05/05/2021
Source: https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified
05/05/2021
| Name | Phase |
|---|---|
| *EU Nodes-AstraZeneca/Oxford COVID-19 vaccine | Phase 3 - completed/published |
| *Serum Institute of India COVID-19 vaccine | Phase 3 - completed/published |
| *SK BIO AstraZeneca/Oxford COVID-19 vaccine | Phase 3 - completed/published |
| Anhui Zhifei COVID-19 vaccine | Phase 3 - ongoing |
| Bharat Biotech COVID-19 vaccine | Phase 3 - ongoing/ partially published |
| Cansino COVID-19 vaccine | Phase 3 - ongoing/ partially published |
| Chumakov COVID-19 vaccine | Phase 1/2 |
| CIGB COVID-19 vaccine | Phase 3 - ongoing |
| FBRI COVID-19 vaccine | Phase 1/2 |
| Gamaleya/Sputnik light COVID-19 vaccine | Phase 3 - ongoing |
| Gamaleya/Sputnik V COVID-19 vaccine | Phase 3 - completed/published |
| Janssen COVID-19 vaccine | Phase 3 - completed |
| Kazakhstan RIBSP COVID-19 vaccine | Phase 3 - ongoing |
| Minhai Biotechnology COVID-19 vaccine | Phase 1/2 |
| Moderna COVID-19 vaccine | Phase 3 - completed/published |
| Pfizer-BioNTech COVID‑19 Vaccine | Phase 3 - completed/published |
| Shifa Pharmed Industrial COVID-19 vaccine | Phase 1/2 |
| Sinopharm-BBIBP COVID-19 vaccine | Phase 3 - ongoing/ partially published |
| Sinopharm-WIBP COVID-19 vaccine | Phase 3 - ongoing |
| Sinovac COVID-19 vaccine | Phase 3 - ongoing/ partially published |
| Takeda COVID-19 vaccine | Phase 1/2 |
| Adopted Name | Name | EUL holder | Manufacturer | Effective date |
|---|---|---|---|---|
| Pfizer-BioNTech COVID-19 vaccine 2BNT162b2; Tozinameran; Comirnaty | Tozinameran - COVD-19 mRNA Vaccine COMIRNATY® | BioNTech Manufacturing GmbH, Germany | BioNTech Manufacturing GmbH, Germany | 31 December 2020 (1) |
| EU Nodes-AstraZeneca/ Oxford COVID-19 vaccine; Vaxzevria in Europe (formerly AZD1222 and ChAdOx1)* | COVID-19 Vaccine (ChAdOx1-S ([recombinant]) | AstraZeneca/SK Bioscience Co. Ltd, Republic of Korea | AstraZeneca/SK Bioscience Co. Ltd, Republic of Korea | 15 February 2021 (2) |
| Serum Institute of India COVID-19 vaccine; Covishield in India* | COVID-19 Vaccine (ChAdOx1-S ([recombinant]) COVISHIELD™ | Serum Institute of India Pvt. Ltd, India | Serum Institute of India Pvt. Ltd, India | 15 February 2021 (3) |
| Janssen COVID-19 vaccine JNJ-78436735; Ad26.COV2-S (recombinant). | COVID-19 Vaccine (Ad26.COV2-S [recombinant]) | Janssen–Cilag International NV, Belgium | Janssen–Cilag International NV, Belgium | 12 March 2021 (4) |
| AstraZeneca/SK BIO COVID-19 vaccine* | COVID-19 Vaccine (ChAdOx1-S ([recombinant]) | AstraZeneca AB, Sweden | Catalent Anagni; CP Pharmaceuticals; | 15 April 2021 (5) |
| ModernaCOVID-19 vaccine mRNA-1273 | COVID-19 mRNA Vaccine (nucleoside modified) | Moderna Biotech | Rovi Pharma Industrial Services, Spain | 30 April 2021 (6) |
| Sinopharm/ BIBP COVID-19 vaccine Inactivated SARS-CoV-2-vaccine (Vero cell); BBIBP-CorV | COVID-19 Vaccine BIBP | Beijing Institute of Biological Products Co., Ltd. (BIBP) | Beijing, China | 07 May 2021 (7) |
| Sinovac COVID-19 vaccine CoronaVac; adsorbed COVID-19 vaccine | COVD-19 mRNA Vaccine (vero cell) inactivated, CoronaVac | Sinovac Life Sciences Co., Ltd. China | Tianfu Street, Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing, P.R. China | 01 june 2021 (8) |
*Vaccines that have different authorizations, but with the same developer.
(1)https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-mrna-vaccine-nucleoside-modified-comirnaty
(2)https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant
(3)https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-covishield
(4)https://extranet.who.int/pqweb/vaccines/who-recommendation-janssen-cilag-international-nv-belgium-covid-19-vaccine-ad26cov2-s
(5)https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-0
(6)https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified
(7)https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp
(8)https://extranet.who.int/pqweb/vaccines/who-recommendation-sinovac-covid-19-vaccine-vero-cell-inactivated-coronavac